Investment funds Orbimed secured $3 billion across two new funds, OrbiMed Private Investments X and OrbiMed Asia Partners VI, to build leading healthcare companies Forbion secured €2.3 billion across two new funds, Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, to invest in high potential biotechs TCGX secured $600 million for […]
iOnctura to present late-breaking data on roginolisib in immunotherapy-resistant NSCLC at SITC iOnctura on Thursday announced that a late-breaking poster evaluating roginolisib in patients with immunotherapy-resistant non-small cell lung cancer (NSCLC) will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8 in Phoenix, Arizona. Exogenus Therapeutics […]
Investment funds Orbimed secured $3 billion across two new funds, OrbiMed Private Investments X and OrbiMed Asia Partners VI, to build leading healthcare companies Forbion secured €2.3 billion across two new funds, Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, to invest in high potential biotechs TCGX secured $600 million for its […]
How are biotech investors using AI to select investments? And how are biotechs themselves using AI to present themselves in the best light? These were some areas covered in a fascinating panel discussion at Optimum’s 18th Annual Healthcare Investment Conference, held at the King’s Fund in early October. And what emerged, is that […]
Gesynta Pharma completes enrolment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care for women with endometriosis, announced that it has completed enrolment in NOVA, its Phase 2 clinical proof-of-concept and dose-finding trial. A total […]
